<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JBC</journal-id>
<journal-id journal-id-type="hwp">spjbc</journal-id>
<journal-title>Journal of Bioactive and Compatible Polymers</journal-title>
<issn pub-type="ppub">0883-9115</issn>
<issn pub-type="epub">1530-8030</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883911512461106</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883911512461106</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Synthesis, characterization, and in vivo evaluation of tumor targeting <italic>N</italic>-(2-hydroxypropyl)methacrylamide copolymer conjugates containing sulfamethazine groups</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yuan</surname><given-names>Jianchao</given-names></name>
<xref ref-type="aff" rid="aff1-0883911512461106">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Li</surname><given-names>Jing</given-names></name>
<xref ref-type="aff" rid="aff1-0883911512461106">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jia</surname><given-names>Zong</given-names></name>
<xref ref-type="aff" rid="aff1-0883911512461106">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Song</surname><given-names>Fengying</given-names></name>
<xref ref-type="aff" rid="aff1-0883911512461106">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Guo</surname><given-names>Hongyun</given-names></name>
<xref ref-type="aff" rid="aff2-0883911512461106">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zeng</surname><given-names>Xianwu</given-names></name>
<xref ref-type="aff" rid="aff2-0883911512461106">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883911512461106"><label>1</label>Key Laboratory of Eco-Environment-Related Polymer Materials of Ministry of Education, Key Laboratory of Polymer Materials of Gansu Province, College of Chemistry and Chemical Engineering, Northwest Normal University, Lanzhou, China</aff>
<aff id="aff2-0883911512461106"><label>2</label>Department of Nuclear Medicine, Gansu Academy of Medical Sciences, Gansu Provincial Tumor Hospital, Lanzhou, China</aff>
<author-notes>
<corresp id="corresp1-0883911512461106">Jianchao Yuan, Key Laboratory of Eco-Environment-Related Polymer Materials of Ministry of Education, Key Laboratory of Polymer Materials of Gansu Province, College of Chemistry and Chemical Engineering, Northwest Normal University, Lanzhou 730070, China. Email: <email>jianchaoyuan@nwnu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>11</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>6</issue>
<fpage>513</fpage>
<lpage>524</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Recent studies have identified that sulfadiazine derivatives can be concentrated in the hepatocellular carcinoma tissue. Herein, we report the synthesis, characterization, and evaluation of a novel sulfamethazine <italic>N</italic>-(2-hydroxypropyl)methacrylamide copolymer conjugates for tumor targeting. <italic>N</italic>-(3-Aminopropyl)methacrylamide-diethylenetriaminepentaacetic acid monomer <bold>1</bold>, methacryloyl-sulfamethazine monomer <bold>2</bold>, poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-sulfamethazine-diethylenetriaminepentaacetic acid conjugate <bold>4</bold>, and poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-sulfamethazine-diethylenetriaminepentaacetic acid-<sup>99m</sup>Tc were successfully synthesized and characterized. Poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-diethylenetriaminepentaacetic acid conjugate <bold>3</bold>, diethylenetriaminepentaacetic acid-<sup>99m</sup>Tc, and poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-diethylenetriaminepentaacetic acid-<sup>99m</sup>Tc were also synthesized and characterized for comparison (<sup>99m</sup>Tc: metastable technetium-99). A 24-h necropsy data in the hepatocellular carcinoma tumor model showed significantly higher (<italic>p</italic> &lt; 0.001) tumor localization for poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-sulfamethazine-diethylenetriaminepentaacetic acid-<sup>99m</sup>Tc (4.82%ID/g ± 0.46%ID/g (percentage injected dose per gram tissue)) compared with poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-diethylenetriaminepentaacetic acid-<sup>99m</sup>Tc (2.69%ID/g ± 0.15%ID/g) and diethylenetriaminepentaacetic acid-<sup>99m</sup>Tc (0.83%ID/g ± 0.03%ID/g). Moreover, higher tumor/organ ratios for poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-sulfamethazine-diethylenetriaminepentaacetic acid-<sup>99m</sup>Tc indicated reduced extravasation of the targeted polymeric conjugates in normal tissues. Thus, the poly(<italic>N</italic>-(2-hydroxypropyl)methacrylamide)-sulfamethazine-diethylenetriaminepentaacetic acid can potentially be used as a macromolecular targeting carrier for hepatocellular carcinoma in mice.</p>
</abstract>
<kwd-group>
<kwd>N-(2-hydroxypropyl)methacrylamide copolymers</kwd>
<kwd>targeted delivery</kwd>
<kwd>sulfamethazine</kwd>
<kwd>biodistribution</kwd>
<kwd>hepatocellular carcinoma</kwd>
<kwd>macromolecular targeting carrier</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0883911512461106" sec-type="intro">
<title>Introduction</title>
<p><italic>N</italic>-(2-hydroxypropyl)methacrylamide (HPMA) copolymers (Mw: 20–40 × 10<sup>3</sup> g/mol; molecular size: 1–100 nm) are frequently used in drug-targeted delivery to enhance permeability and retention (EPR),<sup><xref ref-type="bibr" rid="bibr1-0883911512461106">1</xref><xref ref-type="bibr" rid="bibr2-0883911512461106"/><xref ref-type="bibr" rid="bibr3-0883911512461106"/><xref ref-type="bibr" rid="bibr4-0883911512461106"/><xref ref-type="bibr" rid="bibr5-0883911512461106"/><xref ref-type="bibr" rid="bibr6-0883911512461106"/><xref ref-type="bibr" rid="bibr7-0883911512461106"/>–<xref ref-type="bibr" rid="bibr8-0883911512461106">8</xref></sup> which is less applicable in small tumors.<sup><xref ref-type="bibr" rid="bibr9-0883911512461106">9</xref></sup> Active targeting of specific tumor cell antigens through antibody molecules is being used in drug-targeted delivery; however, antibody targeting of cancer cells still faces obstacles such as limited antigen accessibility and tumor-dependent antigenic heterogeneity.<sup><xref ref-type="bibr" rid="bibr10-0883911512461106">10</xref>,<xref ref-type="bibr" rid="bibr11-0883911512461106">11</xref></sup></p>
<p>Recently, sulfadiazine derivatives were reported to concentrate in the hepatocellular carcinoma tissue.<sup><xref ref-type="bibr" rid="bibr12-0883911512461106">12</xref><xref ref-type="bibr" rid="bibr13-0883911512461106"/><xref ref-type="bibr" rid="bibr14-0883911512461106"/>–<xref ref-type="bibr" rid="bibr15-0883911512461106">15</xref></sup> A high dose of sulfonamide-<sup>99m</sup>Tc (<sup>99m</sup>Tc: metastable technetium-99) remained in the hepatoma after injection (for 5 min, ~4%ID/g (percentage injected dose per gram tissue); for 45 min, ~1.8%ID/g in tumor), indicating that the sulfonamide derivatives could be concentrated in the H22 in mice.<sup><xref ref-type="bibr" rid="bibr12-0883911512461106">12</xref></sup> Antitumor drugs containing sulfadiazine groups exhibited high antitumor activity and low toxicity, indicating the tumor targeting ability of sulfadiazine.<sup><xref ref-type="bibr" rid="bibr13-0883911512461106">13</xref>,<xref ref-type="bibr" rid="bibr14-0883911512461106">14</xref></sup> Several types of antitumor agents possessing sulfonamide have been reported.<sup><xref ref-type="bibr" rid="bibr16-0883911512461106">16</xref><xref ref-type="bibr" rid="bibr17-0883911512461106"/><xref ref-type="bibr" rid="bibr18-0883911512461106"/><xref ref-type="bibr" rid="bibr19-0883911512461106"/>–<xref ref-type="bibr" rid="bibr20-0883911512461106">20</xref></sup> However, HPMA copolymer conjugates containing sulfamethazine (SMZ) groups for targeting delivery of hepatocellular carcinoma have not been reported. In this study, HPMA copolymer and SMZ were selected as a passive targeting carrier and active targeting ligand, respectively, and a combination of both is expected to provide synergistic dual targeting (passive and active) drug delivery system (DDS). Poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc (DTPA: diethylenetriaminepentaacetic acid) as dual targeting DDS, poly(HPMA)-DTPA-<sup>99m</sup>Tc as passive targeting DDS, and DTPA-<sup>99m</sup>Tc as a nontargeting DDS were synthesized and characterized. In order to determine the contributions of the nontargeting, passive targeting, and dual targeting DDSs, their biodistributions were tested and compared on mice bearing hepatoma.</p>
</sec>
<sec id="section2-0883911512461106">
<title>Experimental</title>
<sec id="section3-0883911512461106">
<title>Materials and methods</title>
<p>The HPMA and <italic>N</italic>-(3-aminopropyl)methacrylamide (APMA) were purchased from Polysciences, Inc. (Warrington, PA, USA). Methacryloyl chloride (MA), SMZ, 2,2′-azobisisobutyronitrile (AIBN), thionyl chloride, and DTPA were purchased from Acros (Acros Organics, Geel, Belgium). Dimethyl sulfoxide (DMSO) and acetone were predried with 4 Å molecular sieves and distilled from CaH<sub>2</sub> under dry nitrogen.</p>
<p>Radioactive Na<sup>99m</sup>TcO<sub>4</sub> was obtained from the <sup>99</sup>Mo/<sup>99m</sup>Tc generator (Beijing Atom HighTech Co., Ltd, Beijing, China). Precautions in handling of radioactive compounds are as follows: (1) laboratory coat and gloves must be worn when handling unsealed radioactive material. Monitor hands and change gloves frequently, (2) lead shielding should be used to minimize exposure from Tc-99m, and (3) indirect viewing aids should be used to minimize exposure from Tc-99m.</p>
<p>The mouse hepatoma H22 cell line was obtained from Gansu Academy of Medical Sciences, Gansu Provincial Tumor Hospital (Lanzhou, China). Animal experiments were performed in Kunming mice (male; average weight, ~20 g) obtained from the Animal Center of Lanzhou University (Lanzhou, China). All biodistribution studies were performed under a protocol approved by the Lanzhou Administration Office of Laboratory Animal.</p>
<p>Nuclear magnetic resonance (NMR) spectra were recorded on a Varian Mercury plus-400 instrument, using D<sub>2</sub>O and DMSO-d6 as solvents and tetramethylsilane (TMS) as internal standard. Elemental analyses were performed on a Vario-EL Elemental Analyzer. The molecular weights and molecular weight distributions (MWDs) of the polymers were determined by gel permeation chromatography/size-exclusion chromatography (GPC/SEC) via a Waters Alliance GPCV 2000 chromatograph equipped with refractive index (RI), differential viscometer, and light scattering (90°, right angle laser light scattering (RALLS)) detectors, using 0.2 M NaNO3, 0.01 M NaH<sub>2</sub>PO<sub>4</sub> (pH 7) as the eluent and a 4.6 × 250-mm SynChropak CATSEC-300 column, at a flow rate of 1.0 mL/min and 30°C.</p>
</sec>
<sec id="section4-0883911512461106">
<title>Synthesis of APMA-DTPA monomer <bold>1</bold></title>
<p>The operations were carried out under N<sub>2</sub> atmosphere using standard Schlenk techniques. Thionyl chloride (0.12 g, 1.02 mmol) was slowly added to a stirred solution of DTPA (0.44 g, 1.12 mmol) in DMSO (2 mL) at room temperature. The mixture was then stirred for 5 h at 60°C, cooled, and precipitated with CH<sub>2</sub>Cl<sub>2</sub> (20 mL). The precipitate was separated by filtration and dried under vacuum at room temperature to give the activated DTPA. The activated DTPA was dissolved in DMSO (1 mL), and APMA (0.14 g, 1.0 mmol) was added; the mixture was stirred for 48 h at room temperature. The solution was added slowly to cooled (ice–salt bath) CH<sub>2</sub>Cl<sub>2</sub> (20 mL) with stirring. The precipitate was filtered off, washed with CH<sub>2</sub>Cl<sub>2</sub> thoroughly, and dried at room temperature under vacuum. The precipitate was recrystallized from methanol, washed with cold methanol, and dried under vacuum to give monomer <bold>1</bold> (0.33 g, 64% yield). <sup>1</sup>H-NMR (400 MHz, D<sub>2</sub>O, <italic>δ</italic>, ppm): 5.85 (s, 1H, =C<italic>H<sub>2</sub></italic>), 5.61 (s, 1H, =C<italic>H<sub>2</sub></italic>), 3.80 (s, 8H, –C<italic>H<sub>2</sub></italic>COOH), 3.53 (m, 4H, –C<italic>H<sub>2</sub></italic>CONHC<italic>H<sub>2</sub></italic>CH<sub>2</sub>CH<sub>2</sub>NH–), 3.40 (t, 4H, –NC<italic>H<sub>2</sub></italic>CH<sub>2</sub>N–), 3.22 (t, 4H, –NCH<sub>2</sub>C<italic>H<sub>2</sub></italic>N–), 3.16 (m, 2H, –CH<sub>2</sub>CONHCH<sub>2</sub>CH<sub>2</sub>C<italic>H<sub>2</sub></italic>NH–), 2.07 (m, 5H, –CH<sub>2</sub>CONHCH<sub>2</sub>C<italic>H<sub>2</sub></italic>CH<sub>2</sub>NH– and –C<italic>H<sub>3</sub></italic>). <sup>13</sup>C-NMR (400 MHz, D<sub>2</sub>O, <italic>δ</italic>, ppm): 179.1 (CH<sub>2</sub>═C(CH<sub>3</sub>)<italic>C</italic>ONH–), 175.5 (–CH<sub>2</sub><italic>C</italic>ONHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH–), 174.4 (–CH<sub>2</sub><italic>C</italic>OOH), 141.1 (CH<sub>2</sub>=<italic>C</italic>H–), 125.7 (<italic>C</italic>H<sub>2</sub>=CH–), 59.7 (–<italic>C</italic>H<sub>2</sub>COOH), 58.4 (–<italic>C</italic>H<sub>2</sub>CONHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH–), 54.2 (–N<italic>C</italic>H<sub>2</sub>CH<sub>2</sub>N–), 52.2 (–NCH<sub>2</sub><italic>C</italic>H<sub>2</sub>N–), 39.2 (–CH<sub>2</sub>CONH<italic>C</italic>H<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH–), 38.5 (–CH<sub>2</sub>CONHCH<sub>2</sub>CH<sub>2</sub><italic>C</italic>H<sub>2</sub>NH–), 28.98 (–CH<sub>2</sub>CONHCH<sub>2</sub>CH<sub>2</sub><italic>C</italic>H<sub>2</sub>NH–), 19.9 (–<italic>C</italic>H<sub>3</sub>). Anal. calc. for C<sub>21</sub>H<sub>35</sub>N<sub>5</sub>O<sub>10</sub>: C, 48.74; H, 6.62; N, 13.53. Found: C, 48.79; H, 6.58; N, 13.51.</p>
</sec>
<sec id="section5-0883911512461106">
<title>Synthesis of MA-SMZ monomer <bold>2</bold></title>
<p>MA (0.10 g, 1.00 mmol) was slowly added to a stirred solution of SMZ (0.28 g, 1.00 mmol) and sodium hydroxide (0.04 g, 1 mmol) in H<sub>2</sub>O/acetone (20 mL, 1:1 v/v) at 0°C. The mixture was stirred for 3 h at 0°C and then 12 h at room temperature. The solid was filtered off, washed with cold H<sub>2</sub>O/acetone thoroughly and dried at room temperature under vacuum for 72 h. The crude product was recrystallized from H<sub>2</sub>O/methanol, washed with cold methanol, and dried under vacuum to give monomer <bold>2</bold> (0.29 g, 84% yield). <sup>1</sup>H-NMR (400 MHz, DMSO-d6, <italic>δ</italic>, ppm): 11.64 (s, 1H, –N<italic>H</italic>–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 10.12 (s, 1H, –NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–N<italic>H</italic>–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 7.95 (d, 2H, –NH–C<sub>6</sub><italic>H<sub>2</sub></italic>H<sub>2</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 7.85 (d, 2H, –NH–C<sub>6</sub>H<sub>2</sub><italic>H<sub>2</sub></italic>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 6.74 (s, 1H, –NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub><italic>H</italic>(CH<sub>3</sub>)<sub>2</sub>), 5.82 (s, 1H, C<italic>H</italic>H=C(CH<sub>3</sub>)CO–), 5.55 (s, 1H, CH<italic>H</italic>=C(CH<sub>3</sub>)CO–), 2.25 (s, 6H, –NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(C<italic>H</italic>
<sub>3</sub>)<sub>2</sub>), 1.94 (s, 3H, –C<italic>H</italic>
<sub>3</sub>). <sup>13</sup>C-NMR (400 MHz, DMSO-d6, <italic>δ</italic>, ppm): 167.12 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–<italic>C<sub>3</sub></italic>CN<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 156.29 (CH<sub>2</sub>=C(CH<sub>3</sub>)<italic>C</italic>O–), 142.51 (CH<sub>2</sub>=<italic>C</italic>(CH<sub>3</sub>)CO–), 139.94 (–NH–<italic>C</italic>C<sub>5</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 134.70 (–NH–C<sub>5</sub><italic>C</italic>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 129.10 (–NH–C<sub>3</sub><italic>C<sub>2</sub></italic>CH<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 120.92 (<italic>C</italic>H<sub>2</sub>=C(CH<sub>3</sub>)CO–), 119.06 (–NH–C<sub>3</sub><italic>C<sub>2</sub></italic>CH<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 113.81 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>3</sub><italic>C</italic>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 22.92 (CH<sub>2</sub>=C(<italic>C</italic>H<sub>3</sub>)CO–), 18.84 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(<italic>C</italic>H<sub>3</sub>)<sub>2</sub>). Anal. calc. for C<sub>16</sub>H<sub>18</sub>N<sub>4</sub>O<sub>8</sub>S: C, 55.48; H, 5.24; N, 16.17. Found: C, 55.44; H, 5.26; N, 16.21.</p>
</sec>
<sec id="section6-0883911512461106">
<title>Synthesis of poly(HPMA)-DTPA conjugate <bold>3</bold></title>
<p>Acetone (2.5 mL), DMSO (3.5 mL), HPMA (288 mg, 2.00 mmol), monomer <bold>1</bold> (120 mg, 0.24 mmol), and AIBN (20 mg, 0.012 mmol) were introduced into a 10 mL ampoule and stirred at room temperature to a homogeneous solution. The reaction mixture was sealed under vacuum after deoxygenation by three cycles of nitrogen/vacuum in a dry ice bath. The polymerization was carried out at 50°C for 24 h, the reaction mixture was then cooled to room temperature and filtered. The polymer conjugates (&lt;20k or &gt;40k) were removed by centrifuge filtration using a Vivaspin 2 spin column (molecular weight cutoff (MWCO), 20 or 40 kDa; Vivascience, Hannover, Germany); the polymer conjugates (20k–40k) lyophilized to dryness giving poly(HPMA)-DTPA conjugate as pale yellow powder (228 mg, 56% yield). <sup>1</sup>H-NMR (400 MHz, D<sub>2</sub>O, <italic>δ</italic>, ppm): 3.83 (–C<italic>H<sub>2</sub></italic>COOH of APMA-DTPA), 3.68 (CH<sub>3</sub>C<italic>H</italic>(OH)CH<sub>2</sub>NH– of HPMA), 3.47 (–C<italic>H<sub>2</sub></italic>CONHC<italic>H<sub>2</sub></italic>CH<sub>2</sub>CH<sub>2</sub>NH– of APMA-DTPA), 3.29 (–NHC<italic>H<sub>2</sub></italic>CH<sub>2</sub>NH– of APMA-DTPA), 2.86–3.00 (CH<sub>3</sub>CH(OH)C<italic>H<sub>2</sub></italic>NH– of HPMA and –NHCH<sub>2</sub>C<italic>H<sub>2</sub></italic>NH–, –CH<sub>2</sub>CONHCH<sub>2</sub>C<italic>H<sub>2</sub></italic>C<italic>H<sub>2</sub></italic>NH– of APMA-DTPA), 1.54–1.64 (–C<italic>H</italic>
<sub>2</sub>– of polymer backbone), 0.75–0.96 (–C<italic>H<sub>3</sub></italic>). <sup>13</sup>C-NMR (400 MHz, DMSO-d6, <italic>δ</italic>, ppm): 177.52 (–<italic>C</italic>O–), 177.18 (–<italic>C</italic>O–), 176.43 (–<italic>C</italic>O–), 173.09 (–<italic>C</italic>O–), 65.02 (CH<sub>3</sub><italic>C</italic>H(OH)CH<sub>2</sub>NHCOCCH<sub>3</sub> of HPMA), 55.41 (–<italic>C</italic>H<sub>2</sub>COOH of DTPA), 54.74 (–<italic>C</italic>H<sub>2</sub>CONHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH– of APMA-DTPA), 54.41 (CH<sub>3</sub>CH(OH)<italic>C</italic>H<sub>2</sub>NHCOCCH<sub>3</sub> of HPMA), 52.40 (–NCH<sub>2</sub><italic>C</italic>H<sub>2</sub>N– of DTPA), 48.98 (–N<italic>C</italic>H<sub>2</sub>CH<sub>2</sub>N– of DTPA), 47.56 (–<italic>C</italic>– of polymer backbone), 45.88 (–<italic>C</italic>H<sub>2</sub>– of polymer backbone), 31.58 (–NHCH<sub>2</sub>CH<sub>2</sub><italic>C</italic>H<sub>2</sub>NHCO– of APMA), 30.98 (–NH<italic>C</italic>H<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCO– of APMA), 25.41 (–NHCH<sub>2</sub><italic>C</italic>H<sub>2</sub>CH<sub>2</sub>NHCO– of APMA), 21.65 (–<italic>C</italic>H<sub>3</sub>), 19.64 (–<italic>C</italic>H<sub>3</sub>), 16.21 (–<italic>C</italic>H<sub>3</sub>).</p>
</sec>
<sec id="section7-0883911512461106">
<title>Synthesis of poly(HPMA)-SMZ-DTPA conjugate <bold>4</bold></title>
<p>Acetone (3 mL), DMSO (3 mL), HPMA (218 mg, 1.50 mmol), monomer <bold>1</bold> (52 mg, 0.10 mmol), monomer <bold>2</bold> (34 mg, 0.10 mmol), and AIBN (10 mg, 0.006 mmol) were introduced into a 10 mL ampoule and stirred at room temperature to a homogeneous solution. The reaction mixture was sealed under vacuum after deoxygenation by three cycles of nitrogen/vacuum in a dry ice bath. The polymerization was carried out at 50°C for 24 h, the reaction mixture was cooled to room temperature and filtered. The polymer conjugates (&lt;20k or &gt;40k) were removed by centrifuge filtration using a Vivaspin 2 spin column (MWCO, 20 or 40 kDa; Vivascience); the polymer conjugates (20k–40k) lyophilized to dryness giving poly(HPMA)-DTPA conjugate as pale yellow powder (207 mg, 68% yield). <sup>1</sup>H-NMR (400 MHz, D<sub>2</sub>O, <italic>δ</italic>, ppm): <italic>δ</italic> 7.76 (–NH–C<sub>6</sub><italic>H<sub>2</sub></italic>H<sub>2</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 7.34 (–NH–C<sub>6</sub>H<sub>2</sub><italic>H<sub>2</sub></italic>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 6.50 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub><italic>H</italic>(CH<sub>3</sub>)<sub>2</sub>), 3.85 (–C<italic>H<sub>2</sub></italic>COOH of APMA-DTPA), 3.68 (CH<sub>3</sub> C<italic>H</italic>(OH)CH<sub>2</sub>NH– of HPMA), 3.47 (–C<italic>H<sub>2</sub></italic>CONHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH– of APMA-DTPA), 3.40 (–CH<sub>2</sub>CONHC<italic>H<sub>2</sub></italic>CH<sub>2</sub>CH<sub>2</sub>NH– of APMA-DTPA), 3.29 (–NHC<italic>H<sub>2</sub></italic>CH<sub>2</sub>NH– of APMA-DTPA), 2.66–3.06 (CH<sub>3</sub>CH(OH)C<italic>H<sub>2</sub></italic>NH– of HPMA and –NHCH<sub>2</sub>C<italic>H<sub>2</sub></italic>NH–, –CH<sub>2</sub>CONHCH<sub>2</sub>C<italic>H<sub>2</sub></italic>C<italic>H<sub>2</sub></italic>NH– of APMA-DTPA), 2.47 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(C<italic>H<sub>3</sub></italic>)<sub>2</sub>), 1.33–1.80 (–C<italic>H<sub>2</sub></italic>– of polymer backbone), 0.59–0.98 (–C<italic>H<sub>3</sub></italic>). <sup>13</sup>C-NMR (400 MHz, DMSO-d6, <italic>δ</italic>, ppm): 177.24 (–<italic>C</italic>O–), 172.69 (–<italic>C</italic>O–), 168.26 (–<italic>C</italic>O–), 156.34 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–<italic>C</italic>C<sub>3</sub>N<sub>2</sub>H<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>), 154.62 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<italic>C<sub>2</sub></italic>CN<sub>2</sub>H<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>), 140.05 (–NH–<italic>C</italic>C<sub>5</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–CC<sub>3</sub>N<sub>2</sub>H<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>), 134.24 (–NH–C<sub>5</sub><italic>C</italic>H<sub>4</sub>–SO<sub>2</sub>–NH–CC<sub>3</sub>N<sub>2</sub>H<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>), 126.45 (–NH–C<sub>3</sub><italic>C<sub>2</sub></italic>CH<sub>4</sub>–SO<sub>2</sub>–NH–CC<sub>3</sub>N<sub>2</sub>H<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>), 120.60 (–NH–C<italic>C<sub>2</sub></italic>C<sub>3</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–CC<sub>3</sub>N<sub>2</sub>H<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>), 112.38 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>3</sub><italic>C</italic>N<sub>2</sub>H<sub>3</sub>(CH<sub>3</sub>)<sub>2</sub>), 64.69 (CH<sub>3</sub><italic>C</italic>H(OH)CH<sub>2</sub>NHCOCCH<sub>3</sub> of HPMA), 54.21 (CH<sub>3</sub>CH(OH)<italic>C</italic>H<sub>2</sub>NHCOCCH<sub>3</sub> of HPMA), 52.00 (–<italic>C</italic>H<sub>2</sub>COOH of DTPA), 51.12 (–<italic>C</italic>H<sub>2</sub>CONHCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NH– of APMA-DTPA), 48.55 (–NCH<sub>2</sub><italic>C</italic>H<sub>2</sub>N– of DTPA), 47.86 (–N<italic>C</italic>H<sub>2</sub>CH<sub>2</sub>N– of DTPA), 47.45 (–<italic>C</italic>– of polymer backbone), 44.13 (–<italic>C</italic>H<sub>2</sub>– of polymer backbone), 30.90 (–NHCH<sub>2</sub>CH<sub>2</sub><italic>C</italic>H<sub>2</sub>NHCO– of APMA), 30.62 (–NH<italic>C</italic>H<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>NHCO– of APMA), 29.80 (–NHCH<sub>2</sub><italic>C</italic>H<sub>2</sub>CH<sub>2</sub>NHCO– of APMA), 21.51 (–<italic>C</italic>H<sub>3</sub>), 20.82 (–CH3), 18.21 (–<italic>C</italic>H<sub>3</sub>), 16.69 (–<italic>C</italic>H<sub>3</sub>).</p>
</sec>
<sec id="section8-0883911512461106">
<title>Radiolabeling of DTPA, poly(HPMA)-DTPA, and poly(HPMA)-SMZ-DTPA conjugates with <sup>99m</sup>Tc radionuclide</title>
<p>DTPA, poly(HPMA)-DTPA and poly(HPMA)-SMZ-DTPA conjugates were radiolabeled with <sup>99m</sup>Tc radionuclide by adding Na<sup>99m</sup>TcO<sub>4</sub> into a solution of DTPA, poly(HPMA)-DTPA, and poly(HPMA)-SMZ-DTPA conjugates in 2 mL of 0.1 M sodium acetate buffer (pH 5.5) and incubating at room temperature for 30 min in the presence of SnCl<sub>2</sub>. The labeled poly(HPMA)-DTPA-<sup>99m</sup>Tc and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates were purified by centrifuge filtration using Vivaspin 2 spin column (MWCO, 3 kDa; Vivascience) to separate the conjugates from free <sup>99m</sup>Tc using distilled water as the solvent. Specific activity (µCi/mg) of the poly(HPMA)-DTPA-<sup>99m</sup>Tc and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates was determined by measuring the radioactivity of the conjugates purified with the Vivaspin column. Radiolabeling efficiency was determined by dividing the radioactivity of the purified radiolabeled conjugates by the total radioactivity of the conjugates and the filtrates containing nonconjugated free <sup>99m</sup>Tc radionuclide and then multiplying by 100.</p>
<p>The radiochemical purity of the <sup>99m</sup>Tc-labeled conjugates was also determined using instant thin-layer chromatography. Ethyl acetate, water, and ethanol (5:5:2 v/v) were mixed under stirring. The ester and water phases were separated after standing for 5–10 min. The radiochemical purity of the labeled DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates was determined using instant thin-layer chromatography (No. 1 Xinhua filter paper; Hangzhou Xinhua Group Co., Ltd, Hangzhou, China) with ester phase and water phase as the developing solvent, respectively (ester phase: <sup>99m</sup>Tc-labeled DTPA or copolymer conjugates <italic>R<sub>f</sub></italic> ~ 0, Na<sup>99m</sup>TcO<sub>4</sub> <italic>R<sub>f</sub></italic> ~ 0.5; water phase: <sup>99m</sup>Tc-labeled DTPA or copolymer conjugates <italic>R<sub>f</sub></italic> ~ 0.9, Na<sup>99m</sup>TcO<sub>4</sub> <italic>R<sub>f</sub></italic> ~ 0). Finally, the radiolabeled conjugates dissolved in normal saline were sterilized by filtration with a 0.22-mm Millipore filter prior to use in animal studies.</p>
</sec>
<sec id="section9-0883911512461106">
<title>Implantation of mouse hepatoma cancer xenografts in mice</title>
<p>Animal studies were performed according to a protocol approved by the Lanzhou Administration Office of Laboratory Animal. H22 mouse hepatoma cancer cells (hepatoma (H22) cells were provided by Gansu Academy of Medical Sciences, Gansu Provincial Tumor Hospital, Lanzhou, China) were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. To establish a mouse hepatoma cancer xenograft in mice, H22 cells (5 × 10<sup>6</sup>/injection site) were injected to the right flank of a mouse (male, 4–5 weeks old) purchased from the Animal Center of Lanzhou University. When the tumor xenografts reached about 0.8 × 0.8 cm<sup>2</sup> in size, the tumor-bearing mice were subjected to biodistribution study after intravenous injection of the radiolabeled conjugates.</p>
</sec>
<sec id="section10-0883911512461106">
<title>Biodistribution studies</title>
<p>The tumor-bearing mice were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine (7 mg/kg), and the DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates (200–500 µCi in 0.1 mL normal saline) were injected via the tail vein. At the time of euthanasia, blood samples were collected by cardiac puncture. During necropsy, whole organ tissue samples were obtained from the heart, lung, liver, spleen, kidney, muscle, and tumor. The tissue samples were washed with water, counted (Zhongjia-1200 <italic>γ</italic>-counter; Zhongjia Guangdian Co., Hefei, China), and weighed, and the percentage injected dose per gram tissue was calculated. All biodistribution studies were performed with three mice per group.</p>
</sec>
<sec id="section11-0883911512461106">
<title>Statistical analysis</title>
<p>The values are presented as mean ± standard deviation (SD). An unpaired two-tailed <italic>t</italic> test was used to determine statistical significance using GraphPad InStat software (GraphPad Software, San Diego, CA). A <italic>p</italic> value of &lt;0.05 was considered statistically significant.</p>
</sec></sec>
<sec id="section12-0883911512461106" sec-type="results">
<title>Results</title>
<sec id="section13-0883911512461106">
<title>Synthesis and characterization of DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates</title>
<p>The synthetic pathway for the DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates is shown in <xref ref-type="fig" rid="fig1-0883911512461106">Scheme 1</xref>. The targeting monomer, MA-SMZ, was prepared by a reaction of MA with SMZ (see <xref ref-type="fig" rid="fig1-0883911512461106">Scheme 1</xref>). The radiotracer monomer was synthesized in two steps: (1) DTPA (chelator) reacted with thionyl chloride, because of its multivalent nature, a large excess of DTPA was used to ensure that only one carboxylic acid group is activated and that no undesired cross-linking takes place in the reaction with APMA and (2) the resulting DTPA-Cl was reacted with APMA to form monomer APMA-DTPA via a stable amide bond.</p>
<fig id="fig1-0883911512461106" position="float">
<label>Scheme 1.</label>
<caption>
<p>Synthetic scheme of the DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates.</p>
<p>AIBN: 2,2′-azobisisobutyronitrile; SMZ: sulfamethazine; DTPA: diethylenetriaminepentaacetic acid; HPMA: <italic>N</italic>-(2-hydroxypropyl)methacrylamide; <sup>99m</sup>Tc: metastable technetium-99.</p>
</caption>
<graphic xlink:href="10.1177_0883911512461106-fig1.tif"/></fig>
<p>The polymer conjugates, poly(HPMA)-DTPA and poly(HPMA)-SMZ-DTPA, were synthesized by a conventional free radical precipitation polymerization, and the polymerization conditions, such as initiator concentration, were optimized to obtain polymers with the desired molecular weight.<sup><xref ref-type="bibr" rid="bibr21-0883911512461106">21</xref></sup> Simple centrifuge filtration was sufficient to purify the poly(HPMA)-DTPA and poly(HPMA)-SMZ-DTPA conjugates from unreacted monomers and other low-molecular-weight byproducts. Poly(HPMA) is not a biodegradable polymer, so the target molecular weight (20k–40k g/mol) was selected to ensure ultimate renal elimination (the polymer conjugates (&lt;20k or &gt;40k) were removed by centrifuge filtration using a Vivaspin 2 spin column (MWCO, 20 or 40 kDa; Vivascience)).<sup><xref ref-type="bibr" rid="bibr22-0883911512461106">22</xref></sup></p>
<p>The purified poly(HPMA)-DTPA and poly(HPMA)-SMZ-DTPA conjugates were characterized by <sup>1</sup>H-NMR to determine the content of DTPA and sulfadiazine groups in the conjugates (<xref ref-type="fig" rid="fig2-0883911512461106">Figure 1</xref>). The molecular weight, MWD (polydispersity), and side-chain contents of the poly(HPMA) conjugates are shown in <xref ref-type="table" rid="table1-0883911512461106">Table 1</xref>.</p>
<fig id="fig2-0883911512461106" position="float">
<label>Figure 1.</label>
<caption>
<p><sup>1</sup>H-NMR (400 MHz, D<sub>2</sub>O) of the poly(HPMA)-SMZ-DTPA conjugate.</p>
<p>SMZ: sulfamethazine; DTPA: diethylenetriaminepentaacetic acid; HPMA: <italic>N</italic>-(2-hydroxypropyl)methacrylamide; NMR: nuclear magnetic resonance.</p>
</caption>
<graphic xlink:href="10.1177_0883911512461106-fig2.tif"/></fig>
<table-wrap id="table1-0883911512461106" position="float">
<label>Table 1.</label>
<caption>
<p>Properties of the HPMA copolymers</p>
</caption>
<graphic alternate-form-of="table1-0883911512461106" xlink:href="10.1177_0883911512461106-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Polymer name</th>
<th align="left">SMZ (Mol%)</th>
<th align="left">DTPA (Mol%)</th>
<th align="left">Mn</th>
<th align="left">Mw/Mn</th>
</tr>
</thead>
<tbody>
<tr>
<td>DTPA</td>
<td>—</td>
<td>—</td>
<td>393</td>
<td>—</td>
</tr>
<tr>
<td>Poly(HPMA)-DTPA</td>
<td>—</td>
<td>7.8</td>
<td>2.2 × 10<sup>4</sup></td>
<td>1.4</td>
</tr>
<tr>
<td>Poly(HPMA)-SMZ-DTPA</td>
<td>10.4</td>
<td>9.8</td>
<td>2.5 × 10<sup>4</sup></td>
<td>1.4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0883911512461106"><p>SMZ: sulfamethazine; DTPA: diethylenetriaminepentaacetic acid; HPMA: <italic>N</italic>-(2-hydroxypropyl)methacrylamide.</p></fn>
</table-wrap-foot></table-wrap>
<p>We have used the integral intensities of the –C<italic>H<sub>2</sub></italic>–COOH protons of DTPA (3.83 ppm) and the integral intensity of the CH<sub>3</sub>–C<italic>H</italic>(OH)–CH<sub>2</sub>–NH– protons of the HPMA (3.68 ppm) to calculate the content of DTPA in the poly(HPMA)-DTPA conjugates. On average, the poly(HPMA)-DTPAconjugates contained 7.8 mol% of the monomer units modified with DTPA. Assuming the molecular weight of poly(HPMA) to be 22 kDa that translates into 10 DTPA groups per average polymer chain. The content of SMZ and DTPA in the poly(HPMA)-SMZ-DTPA conjugates was calculated using the integral intensities of the –NH–C<sub>6</sub><italic>H<sub>4</sub></italic>–SO<sub>2</sub>–C<sub>4</sub>N<sub>2</sub><italic>H</italic>(CH<sub>3</sub>)<sub>2</sub> protons of SMZ (7.76 (–NH–C<sub>6</sub><italic>H<sub>2</sub></italic>H<sub>2</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 7.34 (–NH–C<sub>6</sub>H<sub>2</sub><italic>H<sub>2</sub></italic>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub>H(CH<sub>3</sub>)<sub>2</sub>), 6.50 (–NH–C<sub>6</sub>H<sub>4</sub>–SO<sub>2</sub>–NH–C<sub>4</sub>N<sub>2</sub><italic>H</italic>(CH<sub>3</sub>)<sub>2</sub>)), –C<italic>H<sub>2</sub></italic>–COOH protons of DTPA (3.85 ppm), and the integral intensity of the CH<sub>3</sub>–C<italic>H</italic>(OH)–CH<sub>2</sub>–NH– protons of the HPMA (3.68 ppm), respectively (<xref ref-type="fig" rid="fig2-0883911512461106">Figure 1</xref>). On average, the poly(HPMA)-SMZ-DOTA conjugates contained 9.8 and 10.4 mol% of the monomer units modified with DTPA and SMZ, respectively. The copolymers contained approximately 12 DTPA and 13 SMZ units per polymer backbone.</p>
<p>Finally, the DTPA, poly(HPMA)-DTPA, and poly(HPMA)-SMZ-DTPA conjugates were radiolabeled with <sup>99m</sup>Tc radionuclide by incubation of the conjugates with Na<sup>99m</sup>TcO<sub>4</sub> in 2 mL of acetate buffer (pH 5.5) at room temperature for 30 min in the presence of SnCl<sub>2</sub>. Specific activities of DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates were estimated at 200–300 µCi/mg. <sup>99m</sup>Tc radiolabeling of the DTPA and copolymer conjugates achieved efficiencies of &gt;92%. After purification, the radiochemical purities of DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc conjugates were 98.9%, 97.9%, and 98.2%, respectively, which were determined using instant thin-layer chromatography.</p>
</sec>
<sec id="section14-0883911512461106">
<title>Biodistribution studies</title>
<p>The 24-h necropsy radioactivity was expressed as percentage injected dose per gram tissue. In the H22 xenograft model (<xref ref-type="fig" rid="fig3-0883911512461106">Figure 2</xref>), poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc (4.82%ID/g ± 0.46%ID/g) showed significantly higher tumor accumulation (<italic>p</italic> &lt; 0.001) than poly(HPMA)-DTPA-<sup>99m</sup>Tc (2.69%ID/g ± 0.15%ID/g), indicating active targeting of poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc. Poly(HPMA)-DTPA-<sup>99m</sup>Tc (2.69%ID/g ± 0.15%ID/g) showed significantly higher tumor accumulation (<italic>p</italic> &lt; 0.001) than DTPA-<sup>99m</sup>Tc (0.83%ID/g ± 0.03%ID/g), indicating the passive targeting of poly(HPMA)-DTPA-<sup>99m</sup>Tc. Poly(HPMA)-SMZ-DTPA showed significantly lower organ (spleen and kidney) activity compared with poly(HPMA)-DTPA, suggesting greater specific distribution. This means that poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc has both active and passive targeting abilities, poly(HPMA)-DTPA-<sup>99m</sup>Tc does not have active but passive targeting ability, and DTPA-<sup>99m</sup>Tc does not have active and passive targeting ability.</p>
<fig id="fig3-0883911512461106" position="float">
<label>Figure 2.</label>
<caption>
<p>Residual radioactivity in percentage injected dose per gram tissue of organ tissue 24 h after intravenous injection of poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc, poly(HPMA)-DTPA-<sup>99m</sup>Tc, and DTPA-<sup>99m</sup>Tc in H22 hepatoma tumor xenograft bearing. Organ data are expressed as mean ± SD.</p>
<p>SMZ: sulfamethazine; DTPA: diethylenetriaminepentaacetic acid; HPMA: <italic>N</italic>-(2-hydroxypropyl)methacrylamide; NMR: nuclear magnetic resonance; SD: standard deviation; <sup>99m</sup>Tc: metastable technetium-99.</p>
</caption>
<graphic xlink:href="10.1177_0883911512461106-fig3.tif"/></fig>
</sec></sec>
<sec id="section15-0883911512461106" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we performed the following: (1) we conjugated DTPA with the biocompatible, nonimmunogenic, and nontoxic HPMA polymer and labeled the poly(HPMA)-DTPA conjugate with <sup>99m</sup>Tc; (2) for specific targeting on hepatocellular carcinoma, a sulfadiazine moiety was used by conjugating poly(HPMA)-DTPA with SMZ and labeled the poly(HPMA)-SMZ-DTPA conjugate with <sup>99m</sup>Tc; and (3) the tumor targeting efficacy and biodistribution of the conjugates DTPA-<sup>99m</sup>Tc, polyHPMA-DTPA-<sup>99m</sup>Tc, and polyHPMA-SMZ-DTPA-<sup>99m</sup>Tc were evaluated on mice bearing hepatoma.</p>
<p>The HPMA copolymer was used to achieve passive delivery because of its neutral charge; high water solubility; and ease of synthesis, modification, and incorporation of drugs. The lysosomotropic nature of HPMA copolymers was found to guide the DTPA-<sup>99m</sup>Tc to reach its target in vivo.<sup><xref ref-type="bibr" rid="bibr23-0883911512461106">23</xref></sup> Macromolecules have generally been considered to be impermeable to cell membranes and enter cells via endocytosis.<sup><xref ref-type="bibr" rid="bibr24-0883911512461106">24</xref><xref ref-type="bibr" rid="bibr25-0883911512461106"/><xref ref-type="bibr" rid="bibr26-0883911512461106"/>–<xref ref-type="bibr" rid="bibr27-0883911512461106">27</xref></sup></p>
<p>To evaluate the targeting potential of poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc and poly(HPMA)-DTPA-<sup>99m</sup>Tc, their ability to specifically localize to hepatoma tumor was investigated. By dividing the tumor concentration of poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc and poly(HPMA)-DTPA-<sup>99m</sup>Tc to their concentrations in healthy organs and tissues, tumor-to-organ ratios were calculated and used to allow for a more direct and cross-sectional comparison of the tumor targeting ability of poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc and poly(HPMA)-DTPA-<sup>99m</sup>Tc (<xref ref-type="table" rid="table2-0883911512461106">Table 2</xref>). A tumor-to-organ ratio &gt; 1 indicates that accumulation in tumor tissue was more effective, and a ratio &lt; 1 indicates an enhanced localization to healthy tissue. When interpreting all ratios macroscopically, a proper tumor targeting ability was found for poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc. The tumor-to-organ ratios were found to be &gt;1 for liver, blood, lung, spleen, heart, and muscle (<xref ref-type="table" rid="table2-0883911512461106">Table 2</xref>). Only for kidney, the ratios were &lt;1, indicating that the copolymers were cleared from the circulation more rapidly.</p>
<table-wrap id="table2-0883911512461106" position="float">
<label>Table 2.</label>
<caption>
<p>Tumor/organ ratios of poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc and poly(HPMA)-DTPA-<sup>99m</sup>Tc 24 h postintravenous injection</p>
</caption>
<graphic alternate-form-of="table2-0883911512461106" xlink:href="10.1177_0883911512461106-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc</th>
<th align="left">Poly(HPMA)-DTPA-<sup>99m</sup>Tc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart</td>
<td>10.44</td>
<td>4.09</td>
</tr>
<tr>
<td>Lung</td>
<td>5.38</td>
<td>2.51</td>
</tr>
<tr>
<td>Liver</td>
<td>1.62</td>
<td>0.82</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.70</td>
<td>0.35</td>
</tr>
<tr>
<td>Spleen</td>
<td>1.90</td>
<td>0.45</td>
</tr>
<tr>
<td>Muscle</td>
<td>11.25</td>
<td>4.70</td>
</tr>
<tr>
<td>Blood</td>
<td>5.91</td>
<td>2.95</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0883911512461106"><p>SMZ: sulfamethazine; DTPA: diethylenetriaminepentaacetic acid; HPMA: <italic>N</italic>-(2-hydroxypropyl)methacrylamide; <sup>99m</sup>Tc: metastable technetium-99.</p></fn>
</table-wrap-foot></table-wrap>
<p>These results showed that poly(HPMA)-SMZ-DTPA conjugates have the ability of targeting to tumor tissues. Compared to passive delivery vectors such as poly(HPMA)-DTPA conjugates only system, poly(HPMA)-SMZ-DTPA conjugates were found concentrated in tumor site due to the high concentration ratio of tumor to normal tissues. In all cases, passive uptake was always weaker than active endocytosis.</p>
<p>Several groups reported that sulfadiazine derivatives could be concentrated into cancer tissue, although the mechanism of selectivity is still unclear. One possible explanation is that the solubility of sulfadiazine derivatives is highly dependent on pH.<sup><xref ref-type="bibr" rid="bibr15-0883911512461106">15</xref></sup> HPMA copolymer conjugates containing SMZ (~10%) are more soluble at pH above 7 (blood pH ≈ 7.3) and less soluble below this value (carcinoma pH ≈ 6.5). Therefore, the poly(HPMA)-SMZ-DTPA conjugates will accumulate at high concentration in the tumor site than poly(HPMA)-DTPA and DTPA.</p>
</sec>
<sec id="section16-0883911512461106" sec-type="conclusions">
<title>Conclusion</title>
<p>A tumor targeting delivery system was developed based on poly(HPMA)-SMZ-DTPA conjugate. The system consisted of poly(HPMA) carrier, DTPA-<sup>99m</sup>Tc tracer, and targeting ligand SMZ. The poly(HPMA) was used to combine radiotracer APMA-DTPA-<sup>99m</sup>Tc tracer and targeting ligands comonomer MA-SMZ units as targeting tracer carrier. The active and passive delivery system ligand–poly(HPMA)-DTPA-<sup>99m</sup>Tc conjugates could be taken up by hepatocellular carcinoma cells in vivo, when the ligand was SMZ. Thus, the poly(HPMA)-SMZ-DTPA-<sup>99m</sup>Tc can be a potential macromolecular targeting carrier for hepatocellular carcinoma in mice.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This study was financially supported by the National Natural Science Foundation of China (20964003) and Key Laboratory of Eco-Environment-Related Polymer Materials of Ministry of Education, Key Laboratory of Polymer Materials of Gansu Province (Northwest Normal University).</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883911512461106">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ulbrich</surname><given-names>K</given-names></name>
<name><surname>Subr</surname><given-names>V</given-names></name>
</person-group>. <article-title>Structural and chemical aspects of HPMA copolymers as drug carriers</article-title>. <source>Adv Drug Deliv Rev</source> <year>2010</year>; <volume>62</volume>: <fpage>150</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr2-0883911512461106">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Etrych</surname><given-names>T</given-names></name>
<name><surname>Kovář</surname><given-names>L</given-names></name>
<name><surname>Strohalm</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-tumor efficacy</article-title>. <source>J Control Release</source> <year>2011</year>; <volume>3</volume>: <fpage>241</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr3-0883911512461106">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Etrych</surname><given-names>T</given-names></name>
<name><surname>Strohalm</surname><given-names>J</given-names></name>
<name><surname>Chytil</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Biodegradable star HPMA polymer conjugates of doxorubicin for passive tumor targeting</article-title>. <source>Eur J Pharm Sci</source> <year>2011</year>; <volume>42</volume>: <fpage>527</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr4-0883911512461106">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pike</surname><given-names>DB</given-names></name>
<name><surname>Ghandehari</surname><given-names>H</given-names></name>
</person-group>. <article-title>HPMA copolymer-cyclic RGD conjugates for tumor targeting</article-title>. <source>Adv Drug Deliv Rev</source> <year>2010</year>; <volume>62</volume>: <fpage>167</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr5-0883911512461106">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ray</surname><given-names>A</given-names></name>
<name><surname>Larson</surname><given-names>N</given-names></name>
<name><surname>Pike</surname><given-names>DB</given-names></name>
<etal/></person-group>. <article-title>Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates</article-title>. <source>Mol Pharm</source> <year>2011</year>; <volume>8</volume>: <fpage>1090</fpage>–<lpage>1099</lpage>.</citation>
</ref>
<ref id="bibr6-0883911512461106">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Satchi-Fainaro</surname><given-names>R</given-names></name>
<name><surname>Puder</surname><given-names>M</given-names></name>
<name><surname>Davies</surname><given-names>JW</given-names></name>
<etal/></person-group>. <article-title>Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470</article-title>. <source>Nat Med</source> <year>2004</year>; <volume>10</volume>: <fpage>255</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr7-0883911512461106">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kopeček</surname><given-names>J</given-names></name>
<name><surname>Kopečková</surname><given-names>P</given-names></name>
</person-group>. <article-title>HPMA copolymers: origins, early developments, present, and future</article-title>. <source>Adv Drug Deliv Rev</source> <year>2010</year>; <volume>62</volume>: <fpage>122</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr8-0883911512461106">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kostkova</surname><given-names>H</given-names></name>
<name><surname>Etrych</surname><given-names>T</given-names></name>
<name><surname>Rihova</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Synergistic effect of HPMA copolymer-bound doxorubicin and dexamethasone in vivo on mouse lymphomas</article-title>. <source>J Bioact Compat Polym</source> <year>2011</year>; <volume>26</volume>: <fpage>270</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr9-0883911512461106">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>ZR</given-names></name>
<name><surname>Shiah</surname><given-names>JG</given-names></name>
<name><surname>Sakuma</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Design of novel bioconjugates for targeted drug delivery</article-title>. <source>J Control Release</source> <year>2002</year>; <volume>78</volume>: <fpage>165</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr10-0883911512461106">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dvorak</surname><given-names>HF</given-names></name>
<name><surname>Nagy</surname><given-names>JA</given-names></name>
<name><surname>Dvorak</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Structure of solid tumors and their vasculature: implication for therapy with monoclonal antibodies</article-title>. <source>Cancer Cells</source> <year>1991</year>; <volume>3</volume>: <fpage>77</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr11-0883911512461106">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thorpe</surname><given-names>PE</given-names></name>
<name><surname>Wallace</surname><given-names>PM</given-names></name>
<name><surname>Knowles</surname><given-names>PP</given-names></name>
<etal/></person-group>. <article-title>Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulphide linkages</article-title>. <source>Cancer Res</source> <year>1988</year>; <volume>48</volume>: <fpage>6396</fpage>–<lpage>6403</lpage>.</citation>
</ref>
<ref id="bibr12-0883911512461106">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname><given-names>GP</given-names></name>
<name><surname>Zheng</surname><given-names>CY</given-names></name>
<name><surname>Cao</surname><given-names>W</given-names></name>
<etal/></person-group>. <article-title>Synthesis and preliminary evaluation of gadolinium complexes containing sulfonamide groups as potential MRI contrast agents</article-title>. <source>Radiography</source> <year>2003</year>; <volume>9</volume>: <fpage>35</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr13-0883911512461106">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yan</surname><given-names>GP</given-names></name>
<name><surname>Liu</surname><given-names>ML</given-names></name>
<name><surname>Li</surname><given-names>LY</given-names></name>
</person-group>. <article-title>Polyaspartamide gadolinium complexes containing sulfadiazine groups as potential macromolecular MRI contrast Agents</article-title>. <source>Bioconjug Chem</source> <year>2005</year>; <volume>16</volume>: <fpage>967</fpage>–<lpage>971</lpage>.</citation>
</ref>
<ref id="bibr14-0883911512461106">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Z</given-names></name>
<name><surname>Yang</surname><given-names>G</given-names></name>
<name><surname>Lin</surname><given-names>Z</given-names></name>
<etal/></person-group>. <article-title>2-[<italic>N</italic><sup>1</sup>-2-Pyrimidyl-aminobenzenesulfonamido] ethyl 4-bis(2-chloroethyl) aminophenyl butyrate: a potent antitumor agent</article-title>. <source>Bioorg Med Chem Lett</source> <year>2001</year>; <volume>11</volume>: <fpage>1099</fpage>–<lpage>1103</lpage>.</citation>
</ref>
<ref id="bibr15-0883911512461106">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bartulin</surname><given-names>J</given-names></name>
<name><surname>Przybylski</surname><given-names>M</given-names></name>
<name><surname>Ringsdorf</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Pharmacologically active polymers, 6: sulfadiazine and boron derivatives as potential carriers for polymers into cancer tissue</article-title>. <source>Macromol Chem Phys</source> <year>1974</year>; <volume>175</volume>: <fpage>1007</fpage>–<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr16-0883911512461106">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Supuran</surname><given-names>CT</given-names></name>
<name><surname>Scozzafava</surname><given-names>A.</given-names></name>
</person-group> <article-title>Carbonic anhydrase inhibitors—part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?</article-title> <source>Eur J Med Chem</source> <year>2000</year>; <volume>35</volume>: <fpage>867</fpage>–<lpage>874</lpage>.</citation>
</ref>
<ref id="bibr17-0883911512461106">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scozzafava</surname><given-names>A</given-names></name>
<name><surname>Supuran</surname><given-names>CT.</given-names></name>
</person-group> <article-title>Carbonic anhydrase inhibitors: synthesis of <italic>N</italic>-morpholyl-thiocarbonylsulfenylamino aromatic/heterocyclic sulfonamides and their interaction with isozymes I, II and IV</article-title>. <source>Bioorg Med Chem Lett</source> <year>2000</year>; <volume>10</volume>: <fpage>1117</fpage>–<lpage>1120</lpage>.</citation>
</ref>
<ref id="bibr18-0883911512461106">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chern</surname><given-names>JW</given-names></name>
<name><surname>Leu</surname><given-names>YL</given-names></name>
<name><surname>Wang</surname><given-names>SS</given-names></name>
<etal/></person-group>. <article-title>Synthesis and cytotoxic evaluation of substituted sulfonyl-<italic>N</italic>-hydroxyguanidine derivatives as potential antitumor agents</article-title>. <source>J Med Chem</source> <year>1997</year>; <volume>40</volume>: <fpage>2276</fpage>–<lpage>2286</lpage>.</citation>
</ref>
<ref id="bibr19-0883911512461106">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Medina</surname><given-names>JC</given-names></name>
<name><surname>Roche</surname><given-names>D</given-names></name>
<name><surname>Shan</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells</article-title>. <source>Bioorg Med Chem Lett</source> <year>1999</year>; <volume>9</volume>: <fpage>1843</fpage>–<lpage>1846</lpage>.</citation>
</ref>
<ref id="bibr20-0883911512461106">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshino</surname><given-names>H</given-names></name>
<name><surname>Ueda</surname><given-names>N</given-names></name>
<name><surname>Niijima</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Novel sulfonamides as potential, systemically active antitumor agents</article-title>. <source>J Med Chem</source> <year>1992</year>; <volume>35</volume>: <fpage>2496</fpage>–<lpage>2497</lpage>.</citation>
</ref>
<ref id="bibr21-0883911512461106">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rihova</surname><given-names>B</given-names></name>
<name><surname>Bilej</surname><given-names>M</given-names></name>
<name><surname>Vetvicka</surname><given-names>V</given-names></name>
<etal/></person-group>. <article-title>Biocompatibility of <italic>N</italic>-(2-hydroxypropyl) methacrylamide copolymers containing adriamycin</article-title>. <source>Biomaterials</source> <year>1989</year>; <volume>10</volume>: <fpage>335</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr22-0883911512461106">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seymour</surname><given-names>LW</given-names></name>
<name><surname>Miyamoto</surname><given-names>Y</given-names></name>
<name><surname>Maeda</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier</article-title>. <source>Eur J Cancer</source> <year>1995</year>; <volume>31A</volume>: <fpage>766</fpage>–<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr23-0883911512461106">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Omelyanenko</surname><given-names>V</given-names></name>
<name><surname>Kopečková</surname><given-names>P</given-names></name>
<name><surname>Gentry</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate</article-title>. <source>J Control Release</source> <year>1998</year>; <volume>53</volume>: <fpage>25</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr24-0883911512461106">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lencer</surname><given-names>WI</given-names></name>
<name><surname>Weyer</surname><given-names>P</given-names></name>
<name><surname>Verkman</surname><given-names>AS</given-names></name>
<etal/></person-group>. <article-title>FITC-dextran as a probe for endosome function and localization in kidney</article-title>. <source>Am J Physiol Cell Physiol</source> <year>1990</year>; <volume>258</volume>: <fpage>309</fpage>–<lpage>317</lpage>.</citation>
</ref>
<ref id="bibr25-0883911512461106">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naisbett</surname><given-names>B</given-names></name>
<name><surname>Woodley</surname><given-names>J</given-names></name>
</person-group>. <article-title>The potential use of tomato lectin for oral drug delivery: 2. Mechanism of uptake in vitro</article-title>. <source>Int J Pharm</source> <year>1994</year>; <volume>110</volume>: <fpage>127</fpage>–<lpage>136</lpage>.</citation>
</ref>
<ref id="bibr26-0883911512461106">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mero</surname><given-names>A</given-names></name>
<name><surname>Schiavon</surname><given-names>O</given-names></name>
<name><surname>Pasut</surname><given-names>G</given-names></name>
<etal/></person-group>. <article-title>A biodegradable polymeric carrier based on PEG for drug delivery</article-title>. <source>J Bioact Compat Polym</source> <year>2009</year>; <volume>24</volume>: <fpage>220</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr27-0883911512461106">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gan</surname><given-names>YC</given-names></name>
<name><surname>Yuan</surname><given-names>JF</given-names></name>
<name><surname>Liu</surname><given-names>XJ</given-names></name>
<etal/></person-group>. <article-title>ABC triblock copolymers with pH-responsive LCST for controlled drug delivery</article-title>. <source>J Bioact Compat Polym</source> <year>2011</year>; <volume>26</volume>: <fpage>173</fpage>–<lpage>190</lpage>.</citation>
</ref></ref-list>
</back>
</article>